Eli Lilly and Company Snapshot & SWOT Analysis
Eli Lilly and Company (the “company” or “registrant” or 'Lilly') was incorporated in 1901 in Indiana to succeed to the drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly. The company discover, develop, manufacture, and market products in two business segments human pharmaceutical products and animal health products. The company manufacture and distribute their products through facilities in the United States (U.S.), Puerto Rico, and 13 other countries. Their products are sold in approximately 125 countries.
Eli Lilly reported revenue of USD 24.556 billion for the FY 2018 which saw an increase of 7.36% compared to FY 2017. This revenue is expected to increase by 4.25% and reach USD 25.60 billion by FY 2019. Eli Lilly revenue grew at a CAGR of 1.22% during FY 2013 to FY 2018.
In the FY 2018 Eli Lilly registered highest revenue from United States market at USD 13.875 billion which accounted for 56.51% of its total sales, while Rest of the World had the remaining revenue share at USD 10.681 billion accounting for 43.49% of its total sales in FY 2018.
Scope of the Eli Lilly and Company - Company Snapshot & SWOT Analysis Report
Eli Lilly reported revenue of USD 24.556 billion for the FY 2018 which saw an increase of 7.36% compared to FY 2017. This revenue is expected to increase by 4.25% and reach USD 25.60 billion by FY 2019. Eli Lilly revenue grew at a CAGR of 1.22% during FY 2013 to FY 2018.
In the FY 2018 Eli Lilly registered highest revenue from United States market at USD 13.875 billion which accounted for 56.51% of its total sales, while Rest of the World had the remaining revenue share at USD 10.681 billion accounting for 43.49% of its total sales in FY 2018.
Scope of the Eli Lilly and Company - Company Snapshot & SWOT Analysis Report
- This report provides detailed information about Eli Lilly and Company. including value chain analysis, financial performance, business strategy and SWOT analysis.
- The report identifies the growth drivers and inhibitors for global pharmaceutical market.
- This report provides information about current and future trends for global pharmaceutical market.
1. EXECUTIVE SUMMARY
Scope of the Eli Lilly and Company - Company Snapshot & SWOT Analysis Report
Research Methodology
2. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL PHARMACEUTICALS MARKET
3. COMPANY PROFILE
3.1 Eli Lilly and Company
3.1.1 Company Profile
3.1.2 Eli Lilly in Global Pharmaceuticals Manufacturing Value Chain
3.1.3 Eli Lilly: Financial Performance
3.1.3.1 Eli Lilly: Overall Revenue FY 2013-FY 2019 (in USD billion)
3.1.3.2 Eli Lilly: Geography-Wise Revenue FY 2018 (in USD billion)
3.1.3.3 Eli Lilly: Division-Wise Revenue FY 2018 (in USD billion)
3.1.3.4 Eli Lilly: Geography-Wise Pharmaceuticals Revenue FY 2018 (in USD billion)
3.1.3.5 Eli Lilly: Therapy Area-Wise Revenue FY 2018 (in USD billion)
3.1.4 Eli Lilly: Business Strategy
3.1.4.1 Product Level Strategy
3.1.5 SWOT Analysis of Eli Lilly and Company
Strengths
Weaknesses
Opportunities
Threats
4. CURRENT AND FUTURE TRENDS IN PHARMACEUTICAL MARKET
Orphan Drugs
Biologics and Biosimilar
Current Trends
1. INCREASING SEVERITY OF DRUG PRICE CONTROLS
2. GREATER FOCUS ON RARE DISEASES/ORPHAN DRUGS
3. INCREASING DEVELOPMENT OF NUCLEIC ACIDS AS THERAPEUTICS
4. INCREASING FOCUS ON CELL THERAPY
5. IMPLANTABLES (BIOELECTRONICS) AND ELECTROCEUTICALS ARE EXPECTED TO BECOME MAINSTREAM
6. USE OF 3D PRINTING TO REDUCE COST AND IMPROVE PRODUCTION EFFICIENCY OF BIOLOGICS
7. INCREASING USE OF BIG DATA AND ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY
Notes
Company Information
Scope of the Eli Lilly and Company - Company Snapshot & SWOT Analysis Report
Research Methodology
2. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL PHARMACEUTICALS MARKET
3. COMPANY PROFILE
3.1 Eli Lilly and Company
3.1.1 Company Profile
3.1.2 Eli Lilly in Global Pharmaceuticals Manufacturing Value Chain
3.1.3 Eli Lilly: Financial Performance
3.1.3.1 Eli Lilly: Overall Revenue FY 2013-FY 2019 (in USD billion)
3.1.3.2 Eli Lilly: Geography-Wise Revenue FY 2018 (in USD billion)
3.1.3.3 Eli Lilly: Division-Wise Revenue FY 2018 (in USD billion)
3.1.3.4 Eli Lilly: Geography-Wise Pharmaceuticals Revenue FY 2018 (in USD billion)
3.1.3.5 Eli Lilly: Therapy Area-Wise Revenue FY 2018 (in USD billion)
3.1.4 Eli Lilly: Business Strategy
3.1.4.1 Product Level Strategy
3.1.5 SWOT Analysis of Eli Lilly and Company
Strengths
Weaknesses
Opportunities
Threats
4. CURRENT AND FUTURE TRENDS IN PHARMACEUTICAL MARKET
Orphan Drugs
Biologics and Biosimilar
Current Trends
1. INCREASING SEVERITY OF DRUG PRICE CONTROLS
2. GREATER FOCUS ON RARE DISEASES/ORPHAN DRUGS
3. INCREASING DEVELOPMENT OF NUCLEIC ACIDS AS THERAPEUTICS
4. INCREASING FOCUS ON CELL THERAPY
5. IMPLANTABLES (BIOELECTRONICS) AND ELECTROCEUTICALS ARE EXPECTED TO BECOME MAINSTREAM
6. USE OF 3D PRINTING TO REDUCE COST AND IMPROVE PRODUCTION EFFICIENCY OF BIOLOGICS
7. INCREASING USE OF BIG DATA AND ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY
Notes
Company Information
LIST OF EXHIBITS
Exhibit 2.1 Growth Drivers and Inhibitors for Global Pharmaceuticals Market
Exhibit 3.2 Key information of Eli Lilly
Exhibit 3.3 Contact Information Eli Lilly
Exhibit 3.4 Eli Lilly in Pharmaceuticals Manufacturing Value Chain
Exhibit 3.5 Revenue of Eli Lilly and Company FY 2013-FY 2019 (in USD billion
Exhibit 3.6 Revenue Growth of Eli Lilly and Company FY 2014-FY 2019 (in %)
Exhibit 3.7 Geography-Wise Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
Exhibit 3.8 United States Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 3.9 United States Revenue Growth of Eli Lilly and Company FY 2014-FY 2018 (in %)
Exhibit 3.10 Rest of World Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 3.11 Rest of World Revenue Growth of Eli Lilly and Company FY 2014-FY 2018 (in %)
Exhibit 3.12 Division-Wise Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
Exhibit 3.13 Pharmaceuticals Division Revenue of Eli Lilly and Company FY 2013- FY 2018 (in USD billion)
Exhibit 3.14 Animal Health Division Revenue of Eli Lilly and Company FY 2013- FY 2018 (in USD billion)
Exhibit 3.15 Geography-Wise Pharmaceuticals Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
Exhibit 3.16 United States Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 3.17 Europe States Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 3.18 Japan Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 3.19 Rest of World Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 3.20 Therapy Area-Wise Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
Exhibit 3.21 Business Division-Wise, Therapy and Geography Area-Wise Revenue of Eli Lilly and Company FY 2018 (in USD million)
Exhibit 3.22 SWOT Analysis of Eli Lilly and Company
Exhibit 2.1 Growth Drivers and Inhibitors for Global Pharmaceuticals Market
Exhibit 3.2 Key information of Eli Lilly
Exhibit 3.3 Contact Information Eli Lilly
Exhibit 3.4 Eli Lilly in Pharmaceuticals Manufacturing Value Chain
Exhibit 3.5 Revenue of Eli Lilly and Company FY 2013-FY 2019 (in USD billion
Exhibit 3.6 Revenue Growth of Eli Lilly and Company FY 2014-FY 2019 (in %)
Exhibit 3.7 Geography-Wise Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
Exhibit 3.8 United States Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 3.9 United States Revenue Growth of Eli Lilly and Company FY 2014-FY 2018 (in %)
Exhibit 3.10 Rest of World Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 3.11 Rest of World Revenue Growth of Eli Lilly and Company FY 2014-FY 2018 (in %)
Exhibit 3.12 Division-Wise Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
Exhibit 3.13 Pharmaceuticals Division Revenue of Eli Lilly and Company FY 2013- FY 2018 (in USD billion)
Exhibit 3.14 Animal Health Division Revenue of Eli Lilly and Company FY 2013- FY 2018 (in USD billion)
Exhibit 3.15 Geography-Wise Pharmaceuticals Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
Exhibit 3.16 United States Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 3.17 Europe States Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 3.18 Japan Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 3.19 Rest of World Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 3.20 Therapy Area-Wise Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
Exhibit 3.21 Business Division-Wise, Therapy and Geography Area-Wise Revenue of Eli Lilly and Company FY 2018 (in USD million)
Exhibit 3.22 SWOT Analysis of Eli Lilly and Company
